Home » Stocks » CDMO

Avid Bioservices, Inc. (CDMO)

Stock Price: $13.84 USD -0.17 (-1.21%)
Updated Jan 20, 2021 4:00 PM EST - Market closed
Market Cap 838.15M
Revenue (ttm) 72.59M
Net Income (ttm) -5.27M
Shares Out 56.66M
EPS (ttm) -0.08
PE Ratio n/a
Forward PE 78.74
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $13.84
Previous Close $14.01
Change ($) -0.17
Change (%) -1.21%
Day's Open 14.07
Day's Range 13.77 - 14.20
Day's Volume 418,794
52-Week Range 3.15 - 14.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

TUSTIN, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working ...

Other stocks mentioned: CDMOP
GlobeNewsWire - 1 month ago

TUSTIN, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working ...

Other stocks mentioned: CDMOP
GlobeNewsWire - 1 month ago

TUSTIN, Ca., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to ...

Other stocks mentioned: CDMOP
GlobeNewsWire - 1 month ago

TUSTIN, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working ...

Other stocks mentioned: CDMOP
The Motley Fool - 1 month ago

The company reported great fiscal 2021 Q2 results.

Other stocks mentioned: CDMOP
Seeking Alpha - 1 month ago

Avid Bioservices' (CDMO) CEO Nick Green on Q2 2021 Results - Earnings Call Transcript

Other stocks mentioned: CDMOP
Benzinga - 1 month ago

Shares of Avid Bioservices (NASDAQ:CDMO) moved higher by 8.2% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 133.33% over the past ...

Other stocks mentioned: CDMOP
GlobeNewsWire - 1 month ago

-- Recorded Second Quarter Revenue of $ 21 .1 Million -- -- Signed $28 Million in Business Orders and Ended the Quarter with a Backlog of $67 Million --

Other stocks mentioned: CDMOP
GlobeNewsWire - 1 month ago

TUSTIN, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working ...

Other stocks mentioned: CDMOP
GlobeNewsWire - 1 month ago

TUSTIN, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working ...

Other stocks mentioned: CDMOP
GlobeNewsWire - 4 months ago

TUSTIN, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), today announced that it will hold its 2020 Annual Meeting of Stockholders (the “Annual...

Other stocks mentioned: CDMOP
GlobeNewsWire - 4 months ago

TUSTIN, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) worki...

Other stocks mentioned: CDMOP
Seeking Alpha - 4 months ago

Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q1 2021 Results - Earnings Call Transcript

Other stocks mentioned: CDMOP
Benzinga - 4 months ago

Shares of Avid Bioservices (NASDAQ:CDMO) rose 6.81% after the company reported Q1 results.

Other stocks mentioned: CDMOP
GlobeNewsWire - 4 months ago

-- Recorded First Quarter Revenue of $25.4 Million -- -- S igned Three New Customers and Project Expansion Orders with Current Customers for $20 Million --

Other stocks mentioned: CDMOP
GlobeNewsWire - 4 months ago

TUSTIN, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) workin...

Other stocks mentioned: CDMOP
GlobeNewsWire - 4 months ago

TUSTIN, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) workin...

Other stocks mentioned: CDMOP
GlobeNewsWire - 4 months ago

TUSTIN, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) workin...

Other stocks mentioned: CDMOP
GlobeNewsWire - 5 months ago

TUSTIN, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) workin...

Other stocks mentioned: CDMOP
GlobeNewsWire - 5 months ago

Argonaut’s Clinical Fill-Finish Capabilities to Complement Avid’s Upstream and Downstream Process Development and Biologics Manufacturing Services in Supporting Developers of Biologic Therapeu...

Other stocks mentioned: CDMOP
Zacks Investment Research - 6 months ago

Avid Bioservices (CDMO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Other stocks mentioned: CDMOP
The Motley Fool - 6 months ago

The company still had significant production problems. But it also picked up a lot of new business in Q4.

Other stocks mentioned: CDMOP
Zacks Investment Research - 6 months ago

Investors need to pay close attention to Avid Bioservices (CDMO) stock based on the movements in the options market lately.

Other stocks mentioned: CDMOP
Seeking Alpha - 6 months ago

Avid Bioservices, Inc. (CDMO) CEO Richard Hancock on Q4 2020 Results - Earnings Call Transcript

Other stocks mentioned: CDMOP
GlobeNewsWire - 6 months ago

-- Appointed Nicholas Green as President and Chief Executive Officer -- -- Recorded Fourth Quarter Revenue of $12.6 Million and Annual Revenue of $59.7 Million --

Other stocks mentioned: CDMOP
GlobeNewsWire - 6 months ago

Seasoned Executive Brings More than 30 Years of Pharmaceutical and Healthcare Services Industry Experience to Lead Avid Through Next Phase of Growth and Expansion Seasoned Executive Brings Mor...

Other stocks mentioned: CDMOP
Zacks Investment Research - 7 months ago

Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Other stocks mentioned: CDMOP
GlobeNewsWire - 8 months ago

Full Service “Sequence-to-Manufacturing” Offering Designed to Drive Efficiencies and Reduce Overall Timelines for Delivering Early-Stage CGMP Bulk Drug Substances Full Service “Sequence-to-Man...

Other stocks mentioned: CDMOP
The Motley Fool - 8 months ago

These two businesses offer compelling growth potential, but one has yet to deliver on its promise and the other just became more complicated thanks to the coronavirus pandemic.

Other stocks mentioned: ENPH
GlobeNewsWire - 9 months ago

TUSTIN, Calif., April 13, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) worki...

Other stocks mentioned: CDMOP
GlobeNewsWire - 9 months ago

Company Honored for Capabilities, Expertise, Reliability, Compatibility, and Service in the Contract Development and Manufacturing Industry

Other stocks mentioned: CDMOP
The Motley Fool - 10 months ago

The drug manufacturer encountered an operational setback, which forced it to slash revenue guidance.

Other stocks mentioned: CDMOP
Seeking Alpha - 10 months ago

Avid Bioservices, Inc. (CDMO) CEO Richard Hancock on Q3 2020 Results - Earnings Call Transcript

Other stocks mentioned: CDMOP
Zacks Investment Research - 10 months ago

Avid Bioservices (CDMO) delivered earnings and revenue surprises of -100.00% and -19.14%, respectively, for the quarter ended January 2020. Do the numbers hold clues to what lies ahead for the...

Benzinga - 10 months ago

Avid Bioservices (NASDAQ:CDMO) reported Q3 results. Quarterly Results • Earnings per share decreased 20% year over year to a loss of $0.06, which missed the estimate by $0.02.

Other stocks mentioned: CDMOP
GlobeNewsWire - 10 months ago

TUSTIN, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) worki...

Other stocks mentioned: CDMOP
Zacks Investment Research - 10 months ago

Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Other stocks mentioned: CDMOP
GlobeNewsWire - 1 year ago

Company Adds Seasoned Professional with Over 20 Years of Commercial Operations and Sales Team Management Experience Company Adds Seasoned Professional with Over 20 Years of Commercial Operatio...

Other stocks mentioned: CDMOP
24/7 Wall Street - 1 year ago

After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in th...

Other stocks mentioned: ENDP, IGMS, ILMN, ISEE, KOD, MYL, NVCN, PCRX, PFE, XFOR
The Motley Fool - 1 year ago

These two small-cap stocks are risky, but not as risky as penny stocks. And buying a small stake in either company could actually pay off for patient investors.

Other stocks mentioned: PACB
The Motley Fool - 1 year ago

The drug manufacturing company reported operating results for its fiscal second quarter.

Other stocks mentioned: CDMOP
Seeking Alpha - 1 year ago

Avid Bioservices, Inc. (CDMO) CEO Rick Hancock on Q2 2020 Results - Earnings Call Transcript

Other stocks mentioned: CDMOP
Zacks Investment Research - 1 year ago

Avid Bioservices (CDMO) delivered earnings and revenue surprises of 25.00% and 23.74%, respectively, for the quarter ended October 2019. Do the numbers hold clues to what lies ahead for the st...

Other stocks mentioned: CDMOP
GlobeNewsWire - 1 year ago

-- Achieved Strong Second Quarter Revenue of $18.3 Million and Gross Margin of 18% -- -- Fiscal 2020 Projected Revenue of $64 to $67 Million Reaffirmed --

Other stocks mentioned: CDMOP
GlobeNewsWire - 1 year ago

TUSTIN, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) workin...

Other stocks mentioned: CDMOP
Zacks Investment Research - 1 year ago

Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Other stocks mentioned: CDMOP
GlobeNewsWire - 1 year ago

Senior Executive with More than 25 Years of Biopharmaceutical Industry Manufacturing Operations Experience Senior Executive with More than 25 Years of Biopharmaceutical Industry Manufacturing ...

Other stocks mentioned: CDMOP
GlobeNewsWire - 1 year ago

Company to Host Open House to Celebrate Official Launch of Newly Expanded Laboratories Company to Host Open House to Celebrate Official Launch of Newly Expanded Laboratories

Other stocks mentioned: CDMOP
Seeking Alpha - 1 year ago

Avid Bioservices, Inc. (CDMO) CEO Rick Hancock on Q1 2020 Results - Earnings Call Transcript

Other stocks mentioned: CDMOP
The Motley Fool - 1 year ago

Shares jump after the company receives some love from the analyst community.

About CDMO

Avid Bioservices, a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, purification, bulk packaging, release and stability testing, and regulatory submission and support. The company also prov... [Read more...]

Industry
Biotechnology
Founded
1981
Stock Exchange
NASDAQ
Ticker Symbol
CDMO
Full Company Profile

Financial Performance

In 2020, CDMO's revenue was $59.70 million, an increase of 11.38% compared to the previous year's $53.60 million. Losses were -$10.47 million, 148.3% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for CDMO stock is "Strong Buy." The 12-month stock price forecast is 14.33, which is an increase of 3.54% from the latest price.

Price Target
$14.33
(3.54% upside)
Analyst Consensus: Strong Buy